Landras Alexandra, Reger de Moura Coralie, Jouenne Fanelie, Lebbe Celeste, Menashi Suzanne, Mourah Samia
INSERM UMRS 976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), University of Paris, 75010 Paris, France.
Pharmacogenomics Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Saint Louis Hospital, 75010 Paris, France.
Cancers (Basel). 2019 Nov 16;11(11):1803. doi: 10.3390/cancers11111803.
Microenvironment plays a crucial role in tumor development and progression. Cancer cells modulate the tumor microenvironment, which also contribute to resistance to therapy. Identifying biomarkers involved in tumorigenesis and cancer progression represents a great challenge for cancer diagnosis and therapeutic strategy development. CD147 is a glycoprotein involved in the regulation of the tumor microenvironment and cancer progression by several mechanisms-in particular, by the control of glycolysis and also by its well-known ability to induce proteinases leading to matrix degradation, tumor cell invasion, metastasis and angiogenesis. Accumulating evidence has demonstrated the role of CD147 expression in tumor progression and prognosis, suggesting it as a relevant tumor biomarker for cancer diagnosis and prognosis, as well as validating its potential as a promising therapeutic target in cancers.
微环境在肿瘤的发生和发展中起着至关重要的作用。癌细胞会调节肿瘤微环境，而这也会导致对治疗产生抗性。识别参与肿瘤发生和癌症进展的生物标志物是癌症诊断和治疗策略制定面临的巨大挑战。CD147是一种糖蛋白，它通过多种机制参与肿瘤微环境的调节和癌症进展，特别是通过控制糖酵解，以及通过其众所周知的诱导蛋白酶从而导致基质降解、肿瘤细胞侵袭、转移和血管生成的能力。越来越多的证据表明CD147表达在肿瘤进展和预后中所起的作用，这表明它是癌症诊断和预后的相关肿瘤生物标志物，并证实了其作为癌症中有前景的治疗靶点的潜力。
